{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T11:15:24Z","timestamp":1793531724569,"version":"4.5.0"},"reference-count":26,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>N8-GP (turoctocog alfa pegol) is a recombinant, glycoPEGylated, extended half-life, factor VIII replacement product. Here, we examined the immunogenicity, safety, and efficacy of N8-GP in previously untreated patients (PUPs). pathfinder6 is an ongoing, open-label, phase 3 trial that enrolled PUPs with severe hemophilia A and were aged &amp;lt;6 years. The primary end point was the incidence of factor VIII inhibitors (\u22650.6 Bethesda units [BU]). Eighty patients received \u22651 N8-GP dose and were included in this analysis; \u226550 patients had \u226550 exposure days to N8-GP. The inhibitor incidence was 29.9% (14.9% high-titer [&amp;gt;5 BU]). Sixty-five patients received N8-GP prophylaxis for an average of 2.17 years with a median annualized bleeding rate (interquartile range) of 1.42 (0.76; 3.13) and a 90.5% hemostatic success rate. Temporarily decreased incremental recovery (IR), defined as \u22652 consecutive measurements of IR &amp;lt;0.6 (IU\/dL)\/(IU\/kg) but no inhibitors, was observed in 17 patients within 5 exposure days to N8-GP and had a strong temporal correlation with anti\u2013polyethylene glycol immunoglobulin G antibody titers. IR returned within the expected range with continued N8-GP dosing. During the period of decreased IR, hemostatic response was similar to that of the overall trial population, and no hypersensitivity related to N8-GP or unexpected new adverse events were reported. N8-GP prophylaxis was efficacious for the prevention and treatment of bleeding episodes in PUPs with severe hemophilia A. The inhibitor incidence was 29.9%. All patients with temporarily decreased IR continuing on N8-GP dosing returned within the expected range and had no evident lack of efficacy. This trial was registered at www.clinicaltrials.gov as #NCT02137850.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007529","type":"journal-article","created":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T20:56:54Z","timestamp":1658350614000},"page":"620-629","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4989-6421","authenticated-orcid":false,"given":"Christoph","family":"Male","sequence":"first","affiliation":[{"name":"1Department of Paediatrics, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"K\u00f6nigs","sequence":"additional","affiliation":[{"name":"2Department of Pediatrics and Adolescent Medicine, University Hospital, Goethe University, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohan","family":"Dey","sequence":"additional","affiliation":[{"name":"3Novo Nordisk Service Centre India Private Ltd., Bangalore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Matsushita","sequence":"additional","affiliation":[{"name":"4Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Holm","family":"Millner","sequence":"additional","affiliation":[{"name":"5Novo Nordisk A\/S, S\u00f8borg\/M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Zak","sequence":"additional","affiliation":[{"name":"5Novo Nordisk A\/S, S\u00f8borg\/M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6013-1254","authenticated-orcid":false,"given":"Guy","family":"Young","sequence":"additional","affiliation":[{"name":"6Division of Pediatric Hematology\/Oncology, Children\u2019s Hospital Los Angeles\/University of Southern California Keck School of Medicine, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gili","family":"Kenet","sequence":"additional","affiliation":[{"name":"7Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"},{"name":"8The Israeli National Hemophilia Center and Thrombosis Unit, Sheba Medical Center, Tel Hashomer, Israel"},{"name":"9The Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,2,21]]},"reference":[{"issue":"4","key":"2023081515544303300_bib1","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/jth.12161","article-title":"Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A","volume":"11","author":"Tiede","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"issue":"9","key":"2023081515544303300_bib2","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1160\/TH17-03-0166","article-title":"Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A","volume":"117","author":"Meunier","year":"2017","journal-title":"Thromb Haemost"},{"issue":"suppl 1","key":"2023081515544303300_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/jth.15036","article-title":"Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia A: final results from pathfinder5","volume":"18","author":"\u0160aulyt\u0117 Trakymien\u0117","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"suppl 1","key":"2023081515544303300_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jth.14959","article-title":"Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: final results from pathfinder2","volume":"18","author":"Giangrande","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"2023081515544303300_bib5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/2040620712464509","article-title":"Factor VIII inhibitors in hemophilia A: rationale and latest evidence","volume":"4","author":"Witmer","year":"2013","journal-title":"Ther Adv Hematol"},{"issue":"suppl 1","key":"2023081515544303300_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/jth.14958","article-title":"An overview of the pathfinder clinical trials program: long-term efficacy and safety of N8-GP in patients with hemophilia A","volume":"18","author":"Matsushita","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"21","key":"2023081515544303300_bib7","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A\u00a0randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2023081515544303300_bib8","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/blood-2006-11-056317","article-title":"Recombinant versus plasma-derived factor VIII products and\u00a0the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study","volume":"109","author":"Gouw","year":"2007","journal-title":"Blood"},{"key":"2023081515544303300_bib9","unstructured":"European Medicines Agency\n          . Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products, 2021. 2011. Accessed December 2021. Available at:. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-recombinant-human-plasma-derived-factor-viii-products-first-version_en.pdf."},{"issue":"1-2","key":"2023081515544303300_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2006.12.004","article-title":"Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics","volume":"321","author":"Gupta","year":"2007","journal-title":"J\u00a0Immunol Methods"},{"issue":"23","key":"2023081515544303300_bib11","doi-asserted-by":"crossref","first-page":"11804","DOI":"10.1021\/acs.analchem.6b03437","article-title":"Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population","volume":"88","author":"Yang","year":"2016","journal-title":"Anal Chem"},{"issue":"3","key":"2023081515544303300_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood.2019000658","article-title":"Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A","volume":"134","author":"van den Berg","year":"2019","journal-title":"Blood"},{"key":"2023081515544303300_bib13","author":"K\u00f6nigs","year":"5-8  2020"},{"issue":"11","key":"2023081515544303300_bib14","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1055\/s-0040-1722623","article-title":"Simoctocog alfa (Nuwiq) in previously untreated patients with severe haemophilia A: final results of the NuProtect study","volume":"121","author":"Liesner","year":"2021","journal-title":"Thromb Haemost"},{"issue":"6","key":"2023081515544303300_bib15","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1160\/TH11-09-0642","article-title":"Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A","volume":"107","author":"Auerswald","year":"2012","journal-title":"Thromb Haemost"},{"issue":"6","key":"2023081515544303300_bib16","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/hae.13551","article-title":"United Kingdom Haemophilia Centre Doctors\u2019 Organisation Inhibitor Working Party. The immunogenicity of ReFacto AF (moroctocog alfa AF-CC) in previously untreated patients with haemophilia A in the United Kingdom","volume":"24","author":"Mathias","year":"2018","journal-title":"Haemophilia"},{"issue":"3","key":"2023081515544303300_bib17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa1208024","article-title":"Factor VIII products and inhibitor development in severe hemophilia A","volume":"368","author":"Gouw","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023081515544303300_bib18","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/BF02983823","article-title":"Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A","volume":"78","author":"Yoshioka","year":"2003","journal-title":"Int J Hematol"},{"issue":"2","key":"2023081515544303300_bib19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/hae.13119","article-title":"Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A","volume":"23","author":"Mullins","year":"2017","journal-title":"Haemophilia"},{"issue":"6","key":"2023081515544303300_bib20","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/jth.12911","article-title":"Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A","volume":"13","author":"Young","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"2023081515544303300_bib21","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/rth2.12220","article-title":"Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A","volume":"3","author":"Chowdary","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"2023081515544303300_bib22","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1160\/TH16-06-0444","article-title":"Pathfinder\u21222 Investigators. Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A","volume":"117","author":"Giangrande","year":"2017","journal-title":"Thromb Haemost"},{"issue":"3","key":"2023081515544303300_bib23","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1111\/hae.13963","article-title":"PROTECT VIII Kids: BAY 94-9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A","volume":"26","author":"Santagostino","year":"2020","journal-title":"Haemophilia"},{"issue":"4","key":"2023081515544303300_bib24","first-page":"184","article-title":"Subgingival uptake and retention of stannous fluoride from dentifrice: gingival crevicular fluid concentrations in sulci post-brushing","volume":"31","author":"Klukowska","year":"2018","journal-title":"Am J Dent"},{"issue":"1","key":"2023081515544303300_bib25","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.3346\/jkms.2018.33.e5","article-title":"Safety and efficacy of B-domain deleted third generation recombinant factor VIII (GreenGene F\u2122) in Korean patients with hemophilia A: data from a post-marketing surveillance study","volume":"33","author":"Kim","year":"2018","journal-title":"J\u00a0Korean Med Sci"},{"issue":"1","key":"2023081515544303300_bib26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2013.07.026","article-title":"The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage","volume":"172","author":"Abu Lila","year":"2013","journal-title":"J\u00a0Control Release"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/4\/620\/2071316\/blooda_adv-2022-007529-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/4\/620\/2071316\/blooda_adv-2022-007529-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:56:31Z","timestamp":1692114991000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/4\/620\/485991\/The-safety-and-efficacy-of-N8-GP-turoctocog-alfa"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,21]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,2,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007529","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,21]]}}}